UK - SPARK supports $12m series-B funding for Vivacta

Quester, which was acquired by SPARK earlier this year, originally backed the business in March 2006, when it invested just under $6m in series-A funding. This latest investment included contributions for a range of new and existing investors including AGF Private Equity, HBM BioVentures and Viking. The new capital will be used in the commercialisation and launch of the Company's first Point of Care immunoassay system based on its patented piezofilm sensor technology, which can produce laboratory quality results without the need for cell seperation.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland